好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Markers of Bone Turnover and Lipid Metabolism During Eslicarbazepine Acetate (ESL) Monotherapy in Patients Taking or Not Taking Enzyme-Inducing Antiepileptic Drugs (EIAEDs) at Baseline (BL)
Epilepsy/Clinical Neurophysiology (EEG)
(-)
030
Authors/Disclosures
Tawnya M. Constantino, MD (Intermountain NeuroScience Institute)
PRESENTER 		No disclosure on file
Barry E. Gidal, PhD Dr. Gidal has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Eisai . Dr. Gidal has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Greenwich. Dr. Gidal has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for SK life sciences . Dr. Gidal has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eisai. Dr. Gidal has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for SK life science .
Scott Mintzer, MD (Thomas Jefferson Univ) No disclosure on file
Todd Grinnell, PhD Todd Grinnell, PhD has received personal compensation for serving as an employee of Sunovion Pharmaceuticals Inc..
David E. Blum, MD Dr. Blum has received personal compensation for serving as an employee of Neurona Therapeutics. Dr. Blum has stock in Neurona Therapeutics.
Hailong Cheng No disclosure on file